Tekmira announces new results from preclinical anti-viral programs

Tekmira Pharmaceuticals Corporation announced on Tuesday positive results from preclinical tests of the efficacy of TKM-Ebola and TKM-Marburg anti-viral programs in which treatment was delayed after infection.

"We are pleased to see more positive preclinical data validating our LNP technology in multiple anti-viral programs," Dr. Mark J. Murray, the president and CEO of Tekmira, said. "These recent studies with TKM-Ebola and TKM-Marburg demonstrate survival in non-human primates despite delayed treatment after infection with lethal doses of the Ebola and Marburg viruses. Such 'delay to treat' studies in animals infected with lethal doses of rapidly replicating viruses, like Ebola and Marburg, are rigorous tests of anti-viral efficacy in established infections."

TKM-Ebola is an anti-Ebola viral therapeutic, and is developed under a $140 million contract with the U.S. Department of Defense's Joint Project Manager Medical Countermeasure Systems. In preclinical trials, the drug was used to treat infected non-human primates and had a 100 percent protection result from a lethal dose of Zaire Ebola virus, even after delayed treatment.

An infection of the Marburg virus results in death for 90 percent of infected individuals. Data from preclinical trials showed 100 percent survival in non-human primates infected with the Angola strain of Marburg virus when they received treatment.